KCNK18 and migraine disorder: We then show the potential role of TRESK activators as a pain and migraine therapeutic by demonstrating that cloxyquin can ameliorate phenotypes of an in vitro pain model and the chronic nitroglycerine (GTN) in vivo migraine model.